Skip to content
Home/Companies/MedTech/Antelliq

Antelliq

MedTech·France·Exited 2019·Held 6yr
Entry
2013
Hold
6yr
Exit
2019

Who owns Antelliq?

Antelliq is a French MedTech company, now owned by Merck & Co., which acquired it in 2019 from BC Partners.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
BC Partners
Investor
BC Partners
BC European Capital IX · 2012 · Buyout

Key facts

HQFrance
SectorMedTech
Exit Type
Trade Sale
Buyer
Merck & Co.
Exit Year
2019

More from BC European Capital IX

Other portfolio companies in the same fund.

Cigierre
Active
HospitalityItaly· 2015
Pharmathen
Exited 2021
PharmaGreece· 2015
to Partners Group
Acuris
Exited 2019
Business ServicesUK· 2014
to ION Investment Group
CarTrawler
Active
SaaSIreland· 2014
Springer Nature
Springer Nature
Exited 2024
TMTGermany· 2013
Springer SBM
Active
TMTGermany· 2013

More PE-backed in MedTech

Comparable medtech deals from other GPs.

Acufocus, Inc.
Exited 2023
The Carlyle GroupUS
to Bausch + Lomb
Adicon Holdings Limited
Active
The Carlyle GroupUS
Aesynt
Exited 2016
Francisco PartnersUS
to Omnicell
Alere Medical, Inc.
Active
TA AssociatesUS
Alma Lasers, Ltd.
Alma Lasers, Ltd.
Active
TA AssociatesIsrael
Amedes Group
Active
General AtlanticGermany

Questions

Who owns Antelliq?

Antelliq is now owned by Merck & Co., which acquired it in 2019 from BC Partners.

When did Merck & Co. acquire Antelliq?

Merck & Co. acquired Antelliq in 2019, buying from BC Partners.

Who did Antelliq sell to?

BC Partners sold Antelliq to Merck & Co. in 2019 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue